Dr. Peter Geistlich – Pioneer and visionary
Until his death in 2014, Dr. Peter Geistlich was President of the Board of Directors at Geistlich Pharma AG. He has worked at the company since the 1950s. In the 1980s, Dr. Peter Geistlich had the vision of developing in regenerative biomaterials. For this purpose, he established a business division within the Geistlich Group and invested in a new era. Even today, his name stands for the quality of our products and characterises the company in the long term.
Product development with international scientists
In collaboration with international researchers – predominantly with Prof. Dr. Philip J. Boyne from the University of Loma Linda in California - Dr. Peter Geistlich did pioneering work in bone regeneration. For the first time, he freed bone material from organic components – without changing the natural microstructure and bone composition. He thus invented the bone substitute Geistlich Bio-Oss®.
As a second step, Dr. Peter Geistlich developed the natural collagen membrane Geistlich Bio-Gide®. Thanks to its good wound healing properties Geistlich Bio-Gide® facilitates a simple operation technique and fundamentally changed bone regeneration. Geistlich Pharma AG has remained true to the approach of science-based development in collaboration with universities and practitioners – for existing products and new developments.
Combining science with practical application
In 2003, Dr. Peter Geistlich, together with Geistlich Pharma AG, established the Osteology Foundation (Image Movie). With the foundation he created a platform that makes science accessible to industry and practitioners, enabling it to be implemented in practice. In 2013 Dr. Peter Geistlich and Geistlich Pharma AG launched the American Osteo Science Foundation with the objective to establish a platform for funded and entirely independent basic and applied research for new therapy approaches and clinical treatment methods in dental medicine. Accompanying implementation of teaching to establish new knowledge is also a core issue.